Aspirin use tied to longer bladder, breast cancer survival

Aspirin use tied to longer bladder, breast cancer survival

(HealthDay)—Aspirin use may improve survival for bladder and breast cancer, according to a study published online Jan. 15 in JAMA Network Open.

Holli A. Loomans-Kropp, Ph.D., M.P.H., from the National Cancer Institute in Rockville, Maryland, and colleagues investigated the association of aspirin use with the risk for developing new cancers, as well as site-specific cancer-associated survival for , breast, esophageal, gastric, pancreatic, and uterine cancers. The included 139,896 individuals (mean age, 66.4 years) participating in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (1993 to 2001).

The researchers found that aspirin use was not associated with the incidence of any studied cancer type. Aspirin use at least three times/week was associated with increased survival among patients with bladder (hazard ratio, 0.67) and breast (hazard ratio, 0.75) cancers. However, there was no survival benefit with esophageal, gastric, pancreatic, or . A similar association for bladder and was seen for any aspirin use (hazard ratios, 0.75 and 0.79, respectively).

"The results presented here add to the accumulating evidence that aspirin may improve survival for some cancers," the authors write.

More information: Abstract/Full Text

Journal information: JAMA Network Open

Copyright © 2020 HealthDay. All rights reserved.

Citation: Aspirin use tied to longer bladder, breast cancer survival (2021, January 27) retrieved 28 November 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Aspirin use may reduce cancer, all-cause mortality in seniors


Feedback to editors